Hydroxychloroquine COVID-19 trial ends early with few participants
NCT ID NCT04345692
First seen Feb 06, 2026 · Last updated May 16, 2026 · Updated 16 times
Summary
This study aimed to see if hydroxychloroquine, a malaria drug, could help hospitalized COVID-19 patients recover faster. It planned to enroll 350 adults but was stopped early with only 17 participants. The trial compared those who got the drug plus usual care to those who got usual care alone, tracking their health for 28 days.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID-19 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Queen's Medical Center
Honolulu, Hawaii, 96813, United States
Conditions
Explore the condition pages connected to this study.